Summary of the Conference Call for稳健医疗 Company Overview - **Company Name**: 稳健医疗 (Steady Medical) - **Business Segments**: The company operates in two main segments: consumer products (52% of revenue) and medical supplies (48% of revenue) as of Q1 2025. The consumer products segment contributes approximately 60% to the overall operating profit margin [2][3]. Financial Performance - **Revenue Growth**: From 2013 to 2019, the company achieved a revenue growth rate of 24%, primarily driven by the consumer products segment. In Q1 2025, both medical supplies and consumer products segments returned to double-digit growth [2][5]. - **Profitability**: The company expects a 50% year-on-year increase in net profit attributable to the parent company in 2025, with the medical segment projected to grow by approximately 38% [4][19]. Market Dynamics - **Market Size**: The market for wet and dry cotton wipes is valued at over 10 billion yuan, with an expected growth rate of about 7%. The sanitary napkin market is around 100 billion yuan, with a projected retail price increase of about 3% in the coming years [2][6]. - **Market Share**: 全棉时代 (Cotton Era) holds over 15% market share in the facial towel category, while the overall market share of the company exceeds 20%, maintaining the leading position in this category [2][6]. Product Performance - **Core Products**: The core products, including dry and wet cotton wipes and sanitary napkins, have shown significant growth. The sanitary napkin brand, 奈斯公主 (Nice Princess), experienced over 70% year-on-year revenue growth in Q1 2025 [2][7][11]. - **Innovation**: The company introduced a hanging cotton wipe product, which significantly boosted market performance despite being a minor innovation [10]. Consumer Education and Brand Strategy - **Consumer Education**: The company emphasizes consumer education to enhance awareness of the quality and safety of cotton products, which has led to a recovery in double-digit growth for dry and wet cotton wipes [8][9]. - **Brand Positioning**: As a pioneer in the market, the company has established a strong brand identity, leveraging its unique product offerings and consumer education to differentiate itself from competitors [9][20]. Sales Channels - **Channel Distribution**: The consumer products segment has a channel distribution of approximately 60% online and 40% offline. The online sales have been particularly strong on platforms like Douyin [12][13]. - **Store Expansion**: The company operates 487 stores, with plans to open about 50 new stores annually while adjusting the store structure to improve performance [14]. Competitive Landscape - **Market Competition**: The low-value medical consumables market is highly competitive, with domestic brands primarily competing in the low-end market. The company aims to leverage its international presence and product quality to maintain a competitive edge [15][16]. Future Outlook - **Growth Projections**: The company anticipates strong growth in the consumer products segment, with cotton wipes expected to grow by 25% to 30% and sanitary napkins by over 50% in 2025 [18]. - **Net Profit Forecast**: The projected net profit for 2025 is 1.04 billion yuan, with continued growth expected in subsequent years [19]. - **Valuation**: The company's stock is currently valued at a PE ratio of approximately 30 times for 2025, which is considered reasonable given its diversified business model and strong product drivers [21]. Conclusion - **Investment Rating**: The company is viewed positively, with expectations of continued growth and a strong market position, leading to an optimistic outlook for future performance [22].

Group 1: Company Overview - Steady Medical Group, founded in 1991, has evolved into a health enterprise focusing on medical and consumer sectors, listed on the Shenzhen Stock Exchange in 2020 [13] - The company aims to "protect health, care for life, and protect the environment" with its main brands being "Winner Medical" and "Purcotton" [13] Group 2: Annual Performance Review - In 2024, the company achieved a total revenue of 89.8 billion CNY, a 9.7% increase from 2023's 81.9 billion CNY [18] - Excluding infection protection product revenue, the adjusted revenue was 86.2 billion CNY, reflecting an 18.6% year-on-year growth [18] - The revenue structure for 2024 was 43% from medical consumables and 56% from consumer products [18] Group 3: Profitability - The net profit attributable to shareholders reached 7.0 billion CNY, a 19.8% increase compared to 2023 [21] - The net profit margin improved to 7.7%, up 0.7 percentage points from the previous year [21] - The gross profit margin for 2024 was 47.3%, indicating a stable profitability trend [20] Group 4: Asset Quality and R&D Investment - Total assets at the end of 2024 were 184 billion CNY, a 7.5% increase from the previous year [26] - The asset-liability ratio stood at 35.4%, maintaining a low level [26] - The company emphasized R&D, with a steady increase in the number of patents and medical product registrations [26] Group 5: Shareholder Returns - The proposed cash dividend for 2024 is 3.8 billion CNY, representing 54% of the net profit [30] - Cumulative cash dividends since listing amount to 26.1 billion CNY, accounting for 93% of the net proceeds from the IPO [30] Group 6: Medical Consumables Business - The medical segment generated 39.1 billion CNY in revenue for 2024, showing resilience despite a high base from infection protection products [34] - Excluding infection protection, the medical consumables revenue was 35.5 billion CNY, a 20.4% increase year-on-year [34] - Core categories such as high-end dressings and surgical consumables saw revenue growth exceeding 30% [34] Group 7: Consumer Products Business - The consumer segment, led by Purcotton, achieved 49.9 billion CNY in revenue, a 17.1% increase from 2023 [43] - Online sales contributed 62% of the revenue, while offline stores accounted for 30% [46] - The company added 92 new offline stores in 2024, bringing the total to 487 [46] Group 8: Q1 2025 Performance Overview - In Q1 2025, total revenue reached 26.1 billion CNY, a 36.5% increase year-on-year [53] - The medical business revenue for Q1 2025 was 12.5 billion CNY, up 46.3% [54] - The consumer business generated 13.4 billion CNY, reflecting a 28.8% growth [54]

点击注册小程序 2 4 年 医用耗材收入占总收入的比重为 43.5%，收入同比增长1.1%，其中24年9月收购的美国医用耗材公 司GRI贡献收入2.9亿，剔除后收入同比下滑6.4%；毛利率同比下降3.9PCT至36.5%（感染防护产品毛利率 同比下降23.5PCT至21.2%，剔除后其他品类毛利率下降1.1PCT），营业利润率同比下降1.1PCT至7.6%； 25Q1收入同比增长46.3%，剔除GRI并表影响同比增长10.5%。 1）分渠道来看： 2 4 年 海外渠道收入占比为 54.4%，收入同比增长37.7%； 25Q1国外收入同比增长 84.1%，C端业务（国内药店、电商）收入同比增长超40%。 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 24年收入/归母净利润同比+9.7%/+ ...

2025 年 5 月 7 日 公司研究 Q1 业绩表现亮眼，医疗和消费品板块协同发力 ——稳健医疗（300888.SZ）2024 年年报及 2025 年一季报点评 增持（维持） 当前价：52.22 元 作者 分析师：姜浩 执业证书编号：S0930522010001 021-52523680 jianghao@ebscn.com 分析师：孙未未 执业证书编号：S0930517080001 021-52523672 sunww@ebscn.com 分析师：朱洁宇 执业证书编号：S0930523070004 021-52523842 zhujieyu@ebscn.com | 市场数据 | | | --- | --- | | 总股本(亿股) | 5.82 | | 总市值(亿元)： | 304.09 | | 一年最低/最高(元)： | 22.99/54.80 | | 近 3 月换手率： | 61.74% | 股价相对走势 -30% -12% 6% 24% 42% 04/24 07/24 10/24 01/25 稳健医疗 沪深300 | 收益表现 | | | | | --- | --- | --- | --- | | % ...

上 市 公 司 美容护理 | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产（元） | 19.60 | | 资产负债率% | 31.72 | | 总股本/流通 A 股（百万） | 582/176 | | 流通 B 股/H 股（百万） | -/- | 2025 年 05 月 05 日 稳健医疗 (300888) ——两大业务均加速增长，分红率稳步提升 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 04 月 30 日 | | --- | --- | | 收盘价（元） | 52.22 | | 一年内最高/最低（元） | 54.80/23.31 | | 市净率 | 2.7 | | 息率（分红/股价） | 1.72 | | 流通 A 股市值（百万元） | 9,165 | | 上证指数/深证成指 | 3,279.03/9,899.82 | | 注："息率"以最近一年已公布分红计算 | | 一年内股价与大盘对比走势： -40% -20% 0% 20% 40% 60% 80% 04-30 05-31 06-30 07-31 08-31 09-3 ...

2025 年 05 月 05 日 投资评级：买入（维持） | 日期 | 2025/4/30 | | --- | --- | | 当前股价(元) | 52.22 | | 一年最高最低(元) | 54.80/23.31 | | 总市值(亿元) | 304.09 | | 流通市值(亿元) | 91.65 | | 总股本(亿股) | 5.82 | | 流通股本(亿股) | 1.76 | | 近 3 个月换手率(%) | 204.85 | 股价走势图 美容护理/个护用品 2025Q1 净利润高增，消费品业务延续强劲品牌势能 数据来源：聚源 -30% 0% 30% 60% 90% 2024-05 2024-09 2025-01 稳健医疗 沪深300 相关研究报告 《Q3 收入提速重启增长道路，股权激 励彰显信心—公司信息更新报告》 -2024.10.31 《收购 GRI 协同赋能，打造全球耗材 一站式解决方案—公司信息更新报 告》-2024.9.26 《消费高质量增长&医疗恢复增长，看 好新元年向上—公司信息更新报告》 -2024.8.30 | | | ——公司信息更新报告 | | --- | --- | --- | | ...

美容护理/个护用品 2025Q1 净利润高增，消费品业务延续强劲品牌势能 2025 年 05 月 05 日 投资评级：买入（维持） | 日期 | 2025/4/30 | | --- | --- | | 当前股价(元) | 52.22 | | 一年最高最低(元) | 54.80/23.31 | | 总市值(亿元) | 304.09 | | 流通市值(亿元) | 91.65 | | 总股本(亿股) | 5.82 | | 流通股本(亿股) | 1.76 | | 近 3 个月换手率(%) | 204.85 | 股价走势图 数据来源：聚源 -30% 0% 30% 60% 90% 2024-05 2024-09 2025-01 稳健医疗 沪深300 相关研究报告 《Q3 收入提速重启增长道路，股权激 励彰显信心—公司信息更新报告》 -2024.10.31 《收购 GRI 协同赋能，打造全球耗材 一站式解决方案—公司信息更新报 告》-2024.9.26 《消费高质量增长&医疗恢复增长，看 好新元年向上—公司信息更新报告》 -2024.8.30 | | | ——公司信息更新报告 | | --- | --- | --- | | ...

公司报告 | 年报点评报告 稳健医疗（300888） 证券研究报告 品牌健康心智加速消费品业务发展 公司发布年报及一季报 25Q1 公司营收 26 亿同增 36%，归母净利 2.5 亿同增 36%，扣非后归母净 利 2.3 亿同增 62%。 24 年公司营收 90 亿同增 10%，归母净利 7 亿同增 20%，扣非后归母净利 6 亿同增 43%。 24 年医用耗材收入 39 亿占总 44%，同增 1%，毛利率 36.49%同减 4pct。消 费品收入 50 亿占 56%，同增 17%，毛利率 56%，同减 1pct。 24 年医用耗材-传统伤口护理与包扎产品收入 12 亿，占总 13%，同增 4%； 消费品-干湿棉柔巾收入 16 亿，占总 17%，同增 31%；消费品-卫生巾营收 7 亿，占 8%，同增 18%。消费品-婴童服饰及用品收入 10 亿，占总 11%， 同增 13%。 25Q1 医疗板块营收 12.5 亿（其中新并购公司 GRI 营收 3.0 亿），同增 46.3%。 核心品类得到快速发展：手术室耗材、高端敷料、健康个护品类，分别实 现营收 3.7 亿、2.2 亿及 1.2 亿，同增 196.8% ...

证券研究报告 | 年报点评报告 gszqdatemark 2025 05 01 年 月 日 稳健医疗（300888.SZ） 消费业务高速高质增长，靓丽业绩超出预期 2024 年公司收入同比+10%/归母净利润同比+20%。1）2024 年收入为 89.8 亿元，同比+10%； 归母净利润为 7.0 亿元，同比+20%；扣非归母净利润为 5.9 亿元，同比+43%；非经常损益主要 系政府补助及公允价值变动损益。2）盈利质量：2024 全年毛利率同比-1.7pct 至 47.3%；销售/管 理/财务费用率同比分别-0.3/-1.0/-0.3pct 至 25.2%/7.5%/-1.1%；期内计提资产减值损失 2.4 亿 元（同比减少 1.5 亿元）；综合以上，净利率同比+0.6pct 至 8.3%。3）单四季度：2024Q4 收入为 29.1 亿元，同比+34%；归母净利润为 1.4 亿元，净利率为 5.3%。4）公司 2024 年合计拟分配现 金股利 3.79 亿元，股利支付率约为 54%，以 2025 年 4 月 30 日收盘价计算的股息率约为 1.2%。 2025Q1 公司收入同比+36%/归母净利润同比+3 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 60.06 RMB [8][9]. Core Views - The company reported a strong start in Q1 2025, with revenue growth accelerating. For 2024, the company achieved revenue of 8.98 billion RMB, a year-on-year increase of 9.7%, and a net profit of 700 million RMB, up 19.8% year-on-year. The Q1 2025 revenue was 2.61 billion RMB, reflecting a year-on-year growth of 36.5% [1][5]. - The growth in revenue and profit is attributed to the acceleration in consumer goods and the consolidation of GRI in the medical business. The consumer goods segment is showing improvement, and the medical segment has effectively absorbed high base pressures [1][2]. Summary by Sections Consumer Goods - In 2024 and Q1 2025, the health lifestyle consumer goods segment achieved revenues of 4.99 billion RMB and 1.34 billion RMB, respectively, with year-on-year growth of 17.1% and 28.8%. Key product categories such as cotton soft towels and sanitary napkins saw significant growth, with revenues increasing by 31% and 18% respectively in 2024 [2]. Medical Supplies - The medical supplies segment reported revenues of 3.91 billion RMB in 2024 and 1.25 billion RMB in Q1 2025, with year-on-year growth of 1.1% and 46.3%. The infection protection products faced a high base pressure, with a revenue decline of 61.2% in 2024, but this pressure is gradually being absorbed [3]. Financial Metrics - The gross margin for 2024 decreased by 1.7 percentage points to 47.3%, primarily due to rising raw material costs. The expense ratio also decreased by 1.7 percentage points to 35.5%, benefiting from revenue growth diluting expenses [4]. - The company has adjusted its revenue forecasts for 2025-2026 upwards, with expected net profits of 1.06 billion RMB, 1.30 billion RMB, and 1.59 billion RMB for 2025, 2026, and 2027 respectively. The target price is based on a 33 times PE ratio for 2025 [5][9].